Compare HRMY & AMRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | AMRC |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Engineering & Construction |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2020 | 2010 |
| Metric | HRMY | AMRC |
|---|---|---|
| Price | $37.06 | $31.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $49.75 | $33.22 |
| AVG Volume (30 Days) | ★ 612.6K | 531.2K |
| Earning Date | 02-24-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.44 | 18.87 |
| EPS | ★ 3.17 | 1.19 |
| Revenue | $825,944,000.00 | ★ $1,883,767,000.00 |
| Revenue This Year | $23.34 | $9.83 |
| Revenue Next Year | $16.28 | $9.83 |
| P/E Ratio | ★ $11.49 | $22.38 |
| Revenue Growth | ★ 21.13 | 12.22 |
| 52 Week Low | $25.52 | $8.49 |
| 52 Week High | $40.87 | $44.93 |
| Indicator | HRMY | AMRC |
|---|---|---|
| Relative Strength Index (RSI) | 48.18 | 40.58 |
| Support Level | $36.27 | $26.29 |
| Resistance Level | $38.04 | $32.76 |
| Average True Range (ATR) | 1.18 | 1.93 |
| MACD | -0.03 | -0.47 |
| Stochastic Oscillator | 50.14 | 26.23 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Ameresco Inc provides energy efficiency solutions for facilities in North America and Europe. It focuses on projects that reduce energy, also focuses on the operations and maintenance costs of governmental, educational, utility, healthcare, and other institutional, commercial, and industrial entities facilities. Ameresco distributes solar energy products and systems, such as PV panels, solar regulators, solar charge controllers, inverters, solar-powered lighting systems, solar-powered water pumps, solar panel mounting hardware, and other system components. The company's segment includes U.S. Regions; U.S. Federal; Canada; Alternative Fuels; Non-Solar DG and All Other. It derives a majority of its revenue from the U.S. Regions segment.